Aegerion Pharmaceuticals Announces Participation at the Deutsche Bank BioFEST
CAMBRIDGE, Mass., Nov. 28, 2012 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals,
Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the
development and commercialization of novel therapeutics to treat debilitating
and often fatal rare diseases, announced today that the company will
participate at the Deutsche Bank BioFEST Conference in Boston, MA. Marc Beer,
CEO of Aegerion, is scheduled to present on Tuesday, December 4, 2012 at 2:50
The presentation will be webcast live and may be accessed for 90 days
following the conference by visiting the "Investors" section of Aegerion's
About Aegerion Pharmaceuticals, Inc.
Aegerion Pharmaceuticals is an emerging biopharmaceutical company focused on
the development and commercialization of novel, life-altering therapeutics to
treat debilitating and often fatal rare diseases. The company's lead drug
candidate, lomitapide, is in late-stage development for the treatment of
homozygous familial hypercholesterolemia (HoFH), a rare life-threatening
disease characterized by severely elevated cholesterol levels.
Aegerion is motivated by its commitment to patients first, as well as its core
values of integrity, innovation, responsibility to healthcare providers and
development of employees, with a constant focus on scientific and clinical
excellence. For more information, visit www.aegerion.com.
CONTACT: Aegerion Pharmaceuticals, Inc.
Michael Lawless, VP, IR
Press spacebar to pause and continue. Press esc to stop.